Development and Presentation Faculty
Jane Kapustin, PhD, CRNP, BC-ADM, FAANP
Assistant Dean for Master's Programs
University of Maryland School of Nursing
Additional Development Faculty
Dixie L. Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP
Family Nurse Practitioner
Family Medicine of Urbandale
1.0 contact hour of continuing education (which includes 0.50 hours of pharmacology)
THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING April 19, 2011. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Type 2 diabetes (T2DM) has reached an epidemic level in the United States and continues to rise. An estimated 23.6 million people, about 8% of the U.S. population, have T2DM. Uncontrolled T2DM doubles a personís risk for death, and on average, individuals with T2DM lose 10 to 15 years of life. The management of T2DM remains a major clinical challenge for nurse practitioners (NPs) and other healthcare professionals, as a large proportion of patients still do not achieve optimal glycemic control. Moreover, complications and comorbidities that are associated with T2DM, such as macrovascular and microvascular complications, can be overlooked, placing the patient at greater risk for morbidity and mortality. Developing a T2DM treatment strategy that includes strict glucose control and mitigates complications and comorbidities is likely to improve outcomes in patients with this condition. It is therefore imperative that NPs and others who treat T2DM be aware of optimal treatment methods in this patient population. Program Developer/Facilitator
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Incorporate current guideline recommendations into the overall care plan of patients with T2DM.
Integrate patient-centered strategies for intensifying therapy to reach established treatment goals.
Summarize the clinical implications of comorbidities and approaches to prevent or delay their effects.
Identify key resources for T2DM patient education and clinical management.
Dr. Kapustin has no conflicts of interest to disclose.
Dr. Harms discloses that she provides education to community groups on diabetes through educational support from Merck.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.0 contact hour of continuing education (which includes 0.50 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1110338.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an educational grant from Boehringer Ingelheim.
COMPLETING THE POST TEST AND EVALUATION:
When you return to the AANP CE Center, login and find the program you wish to complete. On the programís content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
If you do not have a registration (email and password) with AANP, you will be asked to register: MyAANP. Complete the short profile and create your password to continue in the CE Center. Please contact Stormy Causey, CE Coordinator, at CECenter@aanp.org with any questions.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, or Boehringer Ingelheim.